|
Jun 26
|
Here's Why Beyond Air (XAIR) Could be Great Choice for a Bottom Fisher
|
|
Jun 19
|
Beyond Air Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Jun 18
|
Beyond Air Inc (XAIR) (Q4 2025) Earnings Call Highlights: Revenue Soars Amidst Strategic Global ...
|
|
Jun 17
|
Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
|
|
Jun 16
|
Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH
|
|
Apr 21
|
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism
|
|
Feb 12
|
Beyond Air Third Quarter 2025 Earnings: Beats Expectations
|
|
Feb 10
|
Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
|
|
Oct 2
|
Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks
|
|
Sep 28
|
Beyond Air to sell 40.39M shares at 51c in private placement
|
|
Sep 28
|
Beyond Air terminates loan, security agreements with Avenue Capital
|
|
Sep 27
|
Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed
|
|
Sep 27
|
Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital
|
|
Sep 27
|
Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
|
|
Aug 8
|
Beyond Air First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Aug 6
|
Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update
|
|
Jul 23
|
Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6
|
|
Jun 24
|
Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
|
|
Jun 3
|
Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)
|
|
May 1
|
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
|